Hizentra Approval History
- FDA approved: Yes (First approved March 4th, 2010)
- Brand name: Hizentra
- Generic name: immune globulin subcutaneous (human)
- Company: CSL Behring
- Treatment for: Primary Immunodeficiency Syndrome
Hizentra is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid indicated for the treatment of primary immunodeficiency.
FDA Approval History for Hizentra
|Mar 5, 2010||CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.